Zobrazeno 1 - 10
of 256
pro vyhledávání: '"Walter J. Urba"'
Autor:
David B. Page, Joanna Pucilowska, Brie Chun, Isaac Kim, Katherine Sanchez, Nicole Moxon, Staci Mellinger, Yaping Wu, Yoshinobu Koguchi, Valerie Conrad, William L. Redmond, Maritza Martel, Zhaoyu Sun, Mary B. Campbell, Alison Conlin, Anupama Acheson, Reva Basho, Philomena McAndrew, Mary El-Masry, Dorothy Park, Laura Bennetts, Robert S. Seitz, Tyler J. Nielsen, Kimberly McGregor, Venkatesh Rajamanickam, Brady Bernard, Walter J. Urba, Heather L. McArthur
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-13 (2023)
Abstract Chemoimmunotherapy with anti-programmed cell death 1/ligand 1 and cytotoxic chemotherapy is a promising therapeutic modality for women with triple-negative breast cancer, but questions remain regarding optimal chemotherapy backbone and bioma
Externí odkaz:
https://doaj.org/article/0206d7fb11584f5ab468ac8a9e5bed64
Autor:
Rebekka Duhen, Carmen Ballesteros-Merino, Alexandra K. Frye, Eric Tran, Venkatesh Rajamanickam, Shu-Ching Chang, Yoshinobu Koguchi, Carlo B. Bifulco, Brady Bernard, Rom S. Leidner, Brendan D. Curti, Bernard A. Fox, Walter J. Urba, R. Bryan Bell, Andrew D. Weinberg
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Different neoadjuvant therapies have been proposed to improve immunotherapy for cancer treatment. Here, the authors perform a phase Ib clinical trial where an agonist OX40 antibody provided prior to surgery is well tolerated and increases proliferati
Externí odkaz:
https://doaj.org/article/e0c32b2dd76c42039a82409b6dfffcd3
Autor:
Katherine Sanchez, Isaac Kim, Brie Chun, Joanna Pucilowska, William L. Redmond, Walter J. Urba, Maritza Martel, Yaping Wu, Mary Campbell, Zhaoyu Sun, Gary Grunkemeier, Shu Ching Chang, Brady Bernard, David B. Page
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-15 (2021)
Abstract Background The H&E stromal tumor-infiltrating lymphocyte (sTIL) score and programmed death ligand 1 (PD-L1) SP142 immunohistochemistry assay are prognostic and predictive in early-stage breast cancer, but are operator-dependent and may have
Externí odkaz:
https://doaj.org/article/15073214387d495795317299a2e6cda4
Autor:
Manaz Rezayee, Nicole Moxon, Staci Mellinger, Amanda Y. Seino, Nicole E. Fredrich, Tracy L. Kelly, Susan Mulligan, Ijeoma Uche, Walter J. Urba, Alison K. Conlin, Janet Ruzich, David B. Page
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 4, Iss , Pp 100096- (2021)
Background: Chemotherapy-induced alopecia (CIA) is an emotionally distressing aspect of curative-intent chemotherapy for early stage breast cancer. Manual cold-cap systems are universally available to reduce or prevent CIA, but are costly, with outco
Externí odkaz:
https://doaj.org/article/0e18116042a447eeacf5d1598ed1f36a
Autor:
Marcus A. Couey, R. Bryan Bell, Ashish A. Patel, Meghan C. Romba, Marka R. Crittenden, Brendan D. Curti, Walter J. Urba, Rom S. Leidner
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Abstract Background The risk of delayed autoimmunity occurring months or years after discontinuation of immunotherapy is frequently asserted in the literature. However, specific cases were rarely described until 2018, when a wave of reports surfaced.
Externí odkaz:
https://doaj.org/article/7853dedc4aa84563960981541b8d046a
Autor:
Ryan J. Sullivan, Michael B. Atkins, John M. Kirkwood, Sanjiv S. Agarwala, Joseph I. Clark, Marc S. Ernstoff, Leslie Fecher, Thomas F. Gajewski, Brian Gastman, David H. Lawson, Jose Lutzky, David F. McDermott, Kim A. Margolin, Janice M. Mehnert, Anna C. Pavlick, Jon M. Richards, Krista M. Rubin, William Sharfman, Steven Silverstein, Craig L. Slingluff, Vernon K. Sondak, Ahmad A. Tarhini, John A. Thompson, Walter J. Urba, Richard L. White, Eric D. Whitman, F. Stephen Hodi, Howard L. Kaufman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-23 (2018)
Abstract Background Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination re
Externí odkaz:
https://doaj.org/article/4608673a241f46ca9625955f197bdebe
Autor:
Rachel E. Sanborn, Helen J. Ross, Sandra Aung, Anupama Acheson, Tarsem Moudgil, Sachin Puri, Traci Hilton, Brenda Fisher, Todd Coffey, Christopher Paustian, Michael Neuberger, Edwin Walker, Hong-Ming Hu, Walter J. Urba, Bernard A. Fox
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-14 (2017)
Abstract Background Tumor-derived autophagosome vaccines (DRibbles) have the potential to broaden immune response to poorly immunogenic tumors. Methods Autologous vaccine generated from tumor cells harvested from pleural effusions was administered to
Externí odkaz:
https://doaj.org/article/51a617bc9e0947b2b40212ed699e06aa
Autor:
Rieneke van de Ven, Traci L. Hilton, Hong-Ming Hu, Christopher J. Dubay, Daniel Haley, Christopher Paustian, Sachin Puri, Walter J. Urba, Brendan D. Curti, Sandra Aung, Bernard A. Fox
Publikováno v:
OncoImmunology, Vol 7, Iss 12 (2018)
The immune system plays an essential role in eradicating cancer in concert with various treatment modalities. In the absence of autologous tumor material, no standardized method exists to assess T cell responses against the many antigens that may ser
Externí odkaz:
https://doaj.org/article/15aac23d293c4430b29aebe45cba10a7
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 4, Iss 1 (2016)
Because the benefits of immune checkpoint blockade may be restricted to tumors with pre-existing immune recognition, novel therapies that facilitate de novo immune activation are needed. DRibbles is a novel multi-valent vaccine that is created by dis
Externí odkaz:
https://doaj.org/article/90b7a9b36821475c82fe4cf9ee799ddc
Autor:
Michael B. Atkins, Sandra J. Lee, Bartosz Chmielowski, Ahmad A. Tarhini, Gary I. Cohen, Thach-Giao Truong, Helen H. Moon, Diwakar Davar, Mark O'Rourke, Joseph J. Stephenson, Brendan D. Curti, Walter J. Urba, Joanna M. Brell, Pauline Funchain, Kari L. Kendra, Alexandra P. Ikeguchi, Anthony Jaslowski, Charles L. Bane, Mark A. Taylor, Madhuri Bajaj, Robert M. Conry, Robert J. Ellis, Theodore F. Logan, Noel Laudi, Jeffrey A. Sosman, David G. Crockett, Andrew L. Pecora, Ian J. Okazaki, Sowjanya Reganti, Sunandana Chandra, Samantha Guild, Helen X. Chen, Howard Z. Streicher, Jedd D. Wolchok, Antoni Ribas, John M. Kirkwood
Publikováno v:
Journal of Clinical Oncology. 41:186-197
PURPOSE Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4–blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma, leading to broad regulatory a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5b1385a7ab421246b7bc70886ef74c7
https://doi.org/10.1200/jco.22.01763
https://doi.org/10.1200/jco.22.01763